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Human chromogranin A (hCgA) is a 48-kDa protein with a pI of
4.9, encompassing 439 amino acids (Konecki et al, 1987). It
belongs to the granin family with which it shares numerous struc-
tural and physiological similarities (Simon and Aunis, 1989 for a
review). CgA is largely distributed in secretory granules of
endocrine and neuroendocrine cells and constitutes, with other
members of the granin family, one of their most abundant compo-
nents (Cetin and Grube, 1991).
It has been shown that CgA plays an essential prohormone role
through the release of bioactive peptides produced by its intragran-
ular and extracellular proteolysis of the protein (Barbosa et al,
1991; Metz-Boutigue et al, 1993). Many studies have described
natural peptides in human, as well as in bovine samples, including
pancreastatin, vasostatins/b-granin, chromostatin, WE-14,
parastatin/GE-25 (Iacangelo and Eiden, 1995 for a review) and
prochromacin (Strub et al, 1996). These peptides display several
biological properties, including antibacterial activity as recently
demonstrated by Strub et al (1996) for bovine prochromacin. The
proteolysis concerns mainly the ten dibasic sites distributed along
the hCgA sequence, although other types of cleavage have been
described elsewhere on the sequence (Metz-Boutigue et al, 1993).
It has also been shown that this process is recurrent for C- and N-
terminal ends (Barbosa et al, 1991; Metz-Boutigue et al, 1993).
Furthermore, several studies demonstrated that CgA could be
degraded in a tissue-specific manner, which led to important
disparities in the tissular distribution of the peptides released
(Cetin and Grube, 1991; Curry et al, 1991; Watkinson et al, 1991).
It is likely that the proteolysis properties may be responsible for
the variability of the fragments found in normal and pathological
tissues, blood or urine. Corti et al (1996a) recently confirmed this
diversity by demonstrating the occurrence of different antigenic
profiles among a population of patients affected with phaeochro-
mocytoma. Apart from its differential expression in normal and
neoplastic tissues, many studies have demonstrated the diagnostic
value of hCgA measurement in blood. Levels of total circulating
hCgA are significantly elevated in phaeochromocytomas, carci-
noid and pancreatic endocrine tumours (O’Connor and Deftos,
1986). These data have been confirmed and extended to other
neoplasia: neuroblastoma and gastrointestinal tumours (Eriksson
et al, 1990; Hsiao et al, 1990; Stridsberg et al, 1995). Other authors
have also described how the occurrence of plasma hCgA in
prostatic carcinoma may be the sign of an unfavourable evolution
(Cussenot et al, 1996; Deftos et al, 1996).
Circulating CgA is usually determined by competition assays,
similar to the immunoassay described by O’Connor and Bernstein
(1984), either with radiolabelled or with enzyme-conjugated CgA
(Dillen et al, 1989). More recently, sandwich methods involving
monoclonal or polyclonal antibodies have been published (Bender
et al, 1992; Syversen et al, 1994; Corti et al, 1996a).
The proteolysis of CgA and the multiplicity of circulating frag-
ments suppose an immunoassay configuration able to detect most,
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Summary Chromogranin A (CgA), a major protein of chromaffin granules, has been described as a potential marker for neuroendocrine
tumours. Because of an extensive proteolysis which leads to a large heterogeneity of circulating fragments, its presence in blood has been
assessed in most cases either by competitive immunoassays or with polyclonal antibodies. In the present study, 24 monoclonal antibodies
were raised against native or recombinant human CgA. Their mapping with proteolytic peptides showed that they defined eight distinct
epitopic groups which spanned two-thirds of the C-terminal part of human CgA. All monoclonal antibodies were tested by pair and compared
with a reference radioimmunoassay (RIA) involving CGS06, one of the monoclonal antibodies against the 198–245 sequence. It appears that
CgA C-terminal end seems to be highly affected by proteolysis and the association of C-terminal and median-part monoclonal antibodies is
inadequate for total CgA assessment. Our new immunoradiometric assay involves two monoclonal antibodies, whose contiguous epitopes lie
within the median 145–245 sequence. This assay allows a sensitive detection of total human CgA and correlates well with RIA because
dibasic cleavage sites present in the central domain do not seem to be affected by degradation. It has been proved to be efficient in
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Correspondence to: F Degorceif not all, of these entities. The aim of the present study was to
develop a sandwich assay which would enable the measurement of
intact and fragmented circulating human CgA. We assumed that a
combination of monoclonal antibodies (mAbs) directed against the
median part of the protein, presumably less exposed to proteolysis
because of post-translational modifications (Strub et al, 1997),
would satisfy such requirements. We therefore generated and
selected 24 mAbs against hCgA (human native chromogranin A)
and rhCgA (recombinant human chromogranin A). Epitope
mapping using both Biacore and hCgA proteolytic peptides was
carried out to specifically address the different epitopes to the CgA
protein. Screening of the different mAb pairs against normal and
pathological sera led us to select a sandwich assay, which did not
appear to be affected by hCgA proteolysis because the two mAbs
involved possess contiguous epitopes in the central part of hCgA.
Finally, this new assay has been proved to be efficient in
measuring CgA levels in patients with neuroendocrine tumours.
MATERIALS AND METHODS
Purification of CgAs
Human adrenal phaeochromocytoma was used to purify hCgA
according to the method described previously by O’Connor et al
(1984). Final protein separation was carried out by 2D-gel elec-
trophoresis according to O’Farrell’s original technique (O’Farrell,
1975) modified by Bader and Aunis (1983). CgA was then elec-
troeluted from gels (Metz-Boutigue et al, 1993). Escherichia coli
BL21 (DE3) strain expressing rhCgA was grown as described
elsewhere (Taupenot et al, 1995). Production of rhCgA was
carried out according to the method described by the same authors.
Radioiodination of purified CgA
Purified native or recombinant CgAs were radiolabelled with 125I-
labelled sodium iodide according to the chloramine T method
(Hunter and Greenwood, 1962) at a specific activity of
1500 kBq  mg–1. Free iodine was removed by gel filtration on a
Sephadex-G25 gel (Pharmacia Biotech, Orsay, France). Radio-
labelled protein fractions were pooled and diluted in phosphate-
buffered saline (PBS) pH 7.2 containing 45 mmol l–1 sodium azide
and 0.5% bovine serum albumin (BSA).
Immunizations
Balb/c mice, 6–8 weeks old, were respectively immunized
intraperitoneally with 10 mg of purified hCgA or rhCgA in
Freund’s complete adjuvant. The following intraperitoneal doses
were made in Freund’s incomplete adjuvant at 1-month intervals.
Immunizations of mice were monitored by serum titration via
immunoprecipitation of [125I]hCgA. All animals were handled
according to French law.
Production and screening of hybridomas
The mice were boosted intravenously with 10 mg of hCgA in 0.9%
sodium chloride solution 3 days before cell fusion. Spleen cells
were isolated and fused with myeloma P3-X63 Ag8.653 cell line
in the presence of 37% polyethylene glycol (MW 1540). Positive
clones were identified by immunoprecipitation of [125I]hCgA.
mAbs from positive clones were produced from mouse ascites and
purified using protein A–Sepharose (Pharmacia Biotech).
Mapping of monoclonal antibodies
The different families of CgA epitopes were identified by testing
the possible combinations of mAbs on the Biacore (Biacore, Saint
Quentin-en-Yvelines, France) according to the manufacturer’s
instructions. Biacore is a system for realtime biomolecular inter-
action analysis based on surface plasmon resonance. Briefly, the
sensorchips were prepared by coupling anti-mouse antibodies
(CIS biointernational, Bagnols-sur-Cèze, France) with N-hydroxy-
succinimide and water-soluble carbodiimide before sequential
injection of the following reagents in 200 ml of HEPES buffered
saline 50 mM, EDTA 15 mM, sodium chloride 0.75 M, pH 7.4: (i)
solid phase antibody, (ii) rhCgA at 20  mg ml–1, (iii) mixture of
normal mouse immunoglobulins for saturation at 200 mg ml–1 and
(iv) detecting antibody. All mAbs were injected at 50 mg ml–1. The
sensorchip was regenerated with 0.1 mmol l–1 hydrochloric acid.
Signals expressed in resonance units (RU) allowed us to work out
epitope compatibilities and the performance of the different pairs.
Mapping with rhCgA-derived peptides
Recombinant hCgA (2 nmol) was digested for 2 h at 37°C with
endoproteinase Lys-C or trypsin at a protein/proteinase ratio of
1000:1 in 100 mmol l–1 Tris-HCl, pH 8.3. Generated rhCgA-
derived peptides were then separated on a Macherey Nagel 300-
5C18 column (250 mm ´ 4 mm). Absorbance was monitored at
214 nm, and the solvent system consisted of 0.1% trifluoroacetic
acid in water (solvent A) and 0.1% trifluoroacetic acid in acetoni-
trile (solvent B). Material was eluted at a flow rate of 0.7 ml min–1
using successive gradients of solvent B in A of 0–25% for 10 min
and of 25–75% for 50 min. Each peak fraction was collected and
concentrated by evaporation, but not to complete dryness.
Aliquots of digested rhCgA high-performance liquid chro-
matography (HPLC) fractions were dotted on nitrocellulose
sheets. Membranes were quickly washed with sodium
chloride/inorganic phosphate (25 mM sodium phosphate pH 7.5
containing 0.9% sodium chloride) and incubated for 2 h at room
temperature with mAbs diluted 1:1000 in sodium chloride/
inorganic phosphate. The second antibody was an anti-mouse IgG
conjugated to alkaline phosphatase (Biorad, Ivry-sur-Seine,
France). Enzymatic reaction took place in 100 mmol l–1 Tris-HCl
pH 8.5, 100 mmol l–1 sodium chloride, 50 mmol l–1 magnesium
chloride containing 0.4 mmol l–1 nitro-blue tetrazolium and
0.38 mmol l–1 5-bromo-4-chloro-3-indolyl phosphate (Boehringer
Mannheim, Meylan, France).
The sequence of purified peptides was determined by automatic
Edman degradation on an Applied Biosystems 473A micro-
sequencer. Samples purified by HPLC were loaded on polybrene-
treated and precycled glass-fibre filters (Metz-Boutigue et al,
1993). Phenylthiohydantoin amino acids were identified by chro-
matography on a C-18 column (PTH C-18, 2.1 mm ´ 200 mm).
Mass spectra analysis (Maldi-Tof) was obtained according to the
procedure previously reported (Goumon et al, 1996).
Reference radioimmunoassay for hCgA
mAb CGS06 against hCgA was used to design this RIA (radio-
immunoassay). Purified rhCgA used for the calibrators was
diluted in normal human serum. The calibrator concentrations
ranged from 0 up to 1600 ng ml–1. After combining 50 ml of cali-
brator or sample to be assayed, 300 ml of radiolabelled hCgA
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ng ml–1) in a tube, the first incubation took place for 24 h at room
temperature under gentle shaking. Bound complexes were sepa-
rated for 20 min at room temperature by adding 75 ml of sheep
anti-mouse immunoglobulins diluted to 1:10 in PBS and 50 ml of
human normal serum. One millilitre of 6% polyethylene glycol
(MW 6000) was added and pellets were counted on a g-counter
(Crystal II, Packard Instrument, Rungis, France) after centrifuging
at 2000 g for 15 min (961R, Seroa, Monaco).
Selection of a suitable pair of mAbs for
immunoradiometric assays (IRMA)
mAbs whose epitopes had been mapped to hCgA were used for the
screening of an optimal antibody combination for the measurement
of CgA. All pairs were tested against two pathological plasma
pools from several patient samples with phaeochromocytoma (PP)
and carcinoids (CP) previously assayed in the RIA, as well as
against a pool of plasmas coming from healthy individuals (NP).
Three combinations that involved epitopes spanning the C-
terminal end of the protein (CGS29 and CGS04) were retained for
further testing on a larger population of normal subjects (n = 20) and
of 39 patients suffering from neuroendocrine tumours: phaeochro-
mocytoma, bronchial and intestinal carcinoids, pancreatic endocrine
neoplasia, medullary thyroid carcinoma (MTC). All plasmas were
obtained and used in accordance with local ethical rules.
Experimental procedure
All antibodies were brought to a concentration of 10 mg ml–1 in
PBS pH 7.5 and coated to polystyrene tubes (Greiner France,
Poitiers, France). Concurrently, mAbs were radiolabelled with
125I-labelled sodium iodide using the chloramine T method as
described for rhCgA, at a specific activity of 400 kBq mg–1.
Calibrators were made as described earlier for RIA. Assay buffer
consisted of disodium hydrogen phosphate/potassium dihydrogen
phosphate 50 mmol l–1, EDTA l mmol l–1, sodium azide
15 mmol l–1, BSA 1%, pH 7.0. Briefly, 1 ml of assay buffer and
50 ml of standard or sample were mixed in coated tubes.
Incubation took place for 18 h at room temperature. Tubes were
washed twice with 2 ml of a solution of 0.3% Tween 20. One milli-
litre of radiolabelled mAb was then added to each tube and incu-
bated for 2 h at room temperature under gentle agitation. Tubes
were washed again as previously described and radioactivity was
counted on the g-counter.
RESULTS
Purification of CgA
After microsequencing, the degree of purity of CgA preparations
was checked by 2D-gel electrophoresis as described by Metz-
Boutigue et al (1993). The two-dimensional gel showed a major
spot (70 kDa; pI 5–5.5) corresponding to intact CgA and minor
CgA-derived fragments, the latter representing 5% of total protein.
This pattern of the gel was consistent with results obtained by
Taupenot et al (1995).
Generation of monoclonal antibodies
Two generations of antibodies were obtained with hCgA and
rhCgA respectively (Table 1). Eleven cell fusions were carried out
with mice immunized with hCgA, producing eight hybridomas.
The two cell fusions with animals immunized against the recombi-
nant protein generated 16 different clones. A total of 17 IgG1, six
IgG2a and one IgG2b were produced for further characterization.
Biacore mapping
All possible pairs of mAbs were tested with Biacore using rhCgA.
The 24 mAbs could be distributed into eight distinct groups (Table
1). mAbs from group 3, however, could be further subdivided
because of partial inhibitions existing between CGS10-like anti-
bodies and CGS29, CGS34 and CGS35.
Stoichiometry was determined for each mAb by calculation of
the ratio RU (resonance units) of bound rhCgA/RU of immobi-
lized mAb. Values were found to range from 0.157 to 0.621 mole
rhCgA/mole mAb. No obvious relationship could be established
between the type of immunogen used and the stoichiometry,
except for mAbs from group 3a. In this group, the stoichiometry of
CGS10 and CGS05 raised against human native CgA is signifi-
cantly weaker than that of second generation mAbs against the
recombinant protein.
One mAb of each main group was retained for further character-
ization: CGS04, CGS06, CGS10, CGS17, CGS20, CGS21,
CGS30 and CGS32 were selected. In spite of a weaker stoichiom-
etry, CGS10 and CGS17 were also included in this series because
of better hybridoma productivity.
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Table 1 Characteristics of mAbs obtained. Names in bold type indicate
antibodies raised against native hCgA. Epitope mapping as well as
stoichiometry which is expressed as mole of rhCgA/mole of mAb were
carried out with Biacore. mAb CGS03 stoichiometry could not be tested (n.t.)
Name Isotype Stoichiometry Epitope group
CGS01 IgG1 0.431 1
CGS03 IgG1 n.t.
CGS04 IgG2b 0.365
CGS12 IgG1 0.364
CGS06 IgG2a 0.503 2
CGS08 IgG1 0.457
CGS10 IgG1 0.182 3a
CGS05 IgG1 0.157
CGS23 IgG2a 0.604
CGS24 IgG2a 0.521
CGS25 IgG2a 0.553
CGS26 IgG2a 0.356
CGS29 IgG1 0.621 3b
CGS34 IgG1 0.536
CGS35 IgG1 0.539 3c
CGS30 IgG2a 0.327 4
CGS31 IgG1 0.198
CGS33 IgG1 0.383
CGS36 IgG1 0.184
CGS17 IgG1 0.162 5
CGS19 IgG1 0.361
CGS20 IgG1 0.254 6
CGS21 IgG1 0.183 7
CGS32 IgG1 0.262 8Mapping of monoclonal antibodies after
endoproteinase Lys-C digestion of rhCgA
Recombinant hCgA was digested with endoproteinase Lys-C and
all the mAbs mentioned above were tested against each HPLC
aliquot fraction of digested rhCgA (Figure 1). mAbs CGS17 and
CGS21 recognized the C-terminal domain of the protein with a
high specificity for regions 339–355 and 356–400 respectively
(Figure 2). In addition, mAbs CGS04 and CGS10 were directly
tested by Western blot, and the immunodetected fragments were in
the C-terminal region of CgA (340–394 and 395–439). mAbs
CGS06, CGS20 and CGS30 were specific for the median part of
the protein core 198–245, 246–303 and 145–197 (Figure 2).
Finally, mAb CGS32 was strongly reactive with a large fragment
10–400; this antibody immunodetected a central fragment corre-
sponding to sequence 198–245, but reaction was weak.
Selection of a suitable mAb pair
The two pathological pools (PP and CP) were made from several
EDTA plasmas coming respectively from patients with phaeochro-
mocytoma and intestinal carcinoids. CgA levels, as determined by
the reference RIA, were found to be 675 ng ml–1 for PP and
1600 ng ml–1 for CP. These values were compared with that of the
normal pool which was determined to be 40 ng ml–1 by the refer-
ence RIA.
The results for the 56 mAb combinations tested (Table 2)
show the values obtained for the highest rhCgA calibrator at
1200 ng ml–1, as well as the concentration ratios for PP/NP and
CP/NP. For 26 combinations, CP was out of range and had to be
further diluted. This was also the case for PP in three combinations.
Combinations using CGS21 as a tracer hardly detect rhCgA, as
shown by a bound/total ratio of less than 5% at the 1200 ng ml–1
calibrator. This was also the case, to a minor extent, for tracer
CGS10 (three combinations out of seven and low B/T in general).
All other systems were able to detect rhCgA and showed a signifi-
cant rise in the signal with increasing rhCgA concentrations.
Concerning the detection of CgA in pathological pools, several
types of combinations emerge. First, several systems gave a nega-
tive or a poor discrimination of the pools, i.e. CgA level measured
in PP was never greater than twice that of NP. This situation
applied to most of the combinations involving CGS10 and CGS04,
either immobilized or used as tracers. Systems involving CGS17
or CGS20 gave a weaker discrimination, especially when associ-
ated with antibodies against the 340–439 region of the protein
(CGS17, CGS21, CGS04 and CGS10). This was particularly true
when the two mAbs were used as capture antibodies.
A second behaviour could be identified through systems such
as CGS21/CGS06*, CGS21/CGS30* or CGS32/CGS06* which
discriminated the two pathological pools positively but did not
differentiate them from each other.
Finally, 19 combinations showed PP/NP ratios of greater than 2
as well as high CP/NP ratios, with substantially elevated CgA
levels in CP italic data in Table 2). When the combination of
CGS21/CGS32* is excluded (i.e., the system could not be
reversed), it seems that only heterologous combinations involving
mAbs CGS06, CGS30 and CGS32 were able to measure
increasing CgA concentrations in NP, PP and CP with results close
to the reference RIA. All combinations selected involved epitopes
mapped to the median part of the protein.
To further check these conclusions, three different systems
using tracer mAbs spanning the C-terminal domain of the
protein were tested on a larger population of samples (Figure 3)
and compared with the reference RIA. Because mAb CGS10
behaved poorly as a tracer when associated with CGS06, mAb
CGS29, which shares the same epitope as CGS10, was used for
this experiment.
Analysis of the pathological/normal ratios at the 95th percentile
by Wilcoxon matched-pairs signed-ranks showed that
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Figure 2 Human CgA sequence and position of the different epitopes. Stars
and corresponding numbers indicate the dibasic cleavage sites. mAb CGS32
epitope could not be identified precisely (10–400)
Figure 1 (A) HPLC profile of digested rhCgA with endoprotease Lys-C.
(B) Characteristics of fragments recognized by the different mAbs. mAbs
CGS04 and CGS10 were tested by Western blot and the corresponding
immunodetected spot was sequenced according to Metz-Boutigue et al (1993).
n.d., mass spectroscopy was not carried out for these mAbs; X, non-identified
residue. Location of CgA-derived fragments was obtained according to CgA
sequence (Koneki et al, 1987)Table 2 Evaluation of the different mAb combinations on normal vs pathological plasma pools
Solid Tracers
phases
CGS32 CGS30 CGS06 CGS20 CGS17 CGS21 CGS04 CGS10
48.13a 30.89 7.01 15.63 3.01 32.17 3.53
CGS32 16.4b 24.3 8.8 4.3 18.0 1.9 1.0
23.3c 28.1 50.3 28.0 39.6 15.6 9.3
21.56 57.56 22.04 29.2 3.38 60.57 9.40
CGS30 10.9 16.0 5.6 3.0 14.4 1.2 0.5
17.7 25.0 21.8 29.2 31.3 9.3 7.5
18.8 65.51 12.8 20.38 2.6 45.17 3.92
CGS06 11.3 9.9 4.0 1.6 8.0 1.0 0.9
18.5 18.2 23.2 22.0 18.5 10.6 3.8
15.11 43.22 25.43 8.29 1.42 30.70 1.61
CGS20 1.3 2.6 2.0 1.7 2.5 0.8 0.0
10.2 12.8 15.6 26.6 11.3 7.6 0.9
17.67 62.66 49.52 21.29 2.7 60.86 7.81
CGS17 2.3 2.4 2.3 2.0 2.4 1.0 0.5
14.2 22.4 24.0 20.9 20.7 10.4 5.4
15.86 67.46 50.52 15.4 27.53 48.57 7.82
CGS21 9.6 13.0 16.2 5.5 3.3 1.1 0.0
20.4 14.6 16.2 11.7 19.4 5.5 0.7
28.83 76.53 55.53 26.71 55.05 3.62 19.57
CGS04 1.1 1.2 1.1 1.1 0.9 1.2 0.7
4.7 13.5 28.2 24.3 17.3 14.3 16.4
12.39 33.96 17.49 7.77 11.65 1.44 30.54
CGS10 0.1 0.7 0.8 0.5 0.5 0.9 0.6
3.9 5.0 9.0 6.1 4.0 4.0 4.3
aPer cent binding at 1200 ng ml–1 of rhCgA. b and cCgA concentration ratios PP/NP and CP/NP respectively. Dark
grey squares indicate low-sensitivity systems. Light grey squares stand for negative or poor discriminative systems.
White squares with underlined italic type show combinations that discriminate PP and CP positively as well as one
from the other. Ratios of PP/NP and CP/NP were found to be 16.9 and 40 in the reference RIA.
CGS06/CGS30* and the reference RIA, as well as
CGS06/CGS04* and the RIA, are closely related (P < 0.0001 and
P = 0.011 respectively). In contrast, CGS06/CGS29* is signifi-
cantly different from the RIA (P = 0.738). The CGS06/CGS30*
combination with two contiguous epitopes within the median part
of CgA gave a very similar distribution of the samples when
compared with the RIA. Normal values ranged from 33 to
94 ng ml–1 and the cut-off value was fixed at 86 ng ml–1 (95th
percentile of normal population). However, the use of CGS29
tracer, whose epitope is CGS10-like, led to a dramatic decrease in
the concentrations measured. The rhCgA calibrator at 1200 ng
ml–1 was detected at a significant level (20% of B/T). However,
concentrations measured for normal plasmas ranged from 0 to
55 ng ml–1 and CgA level was undetectable in 50% of the popula-
tion. With this system, only two samples could be measured above
the cut-off (30 ng ml–1) and they both came from patients with
intestinal carcinoids. Furthermore, 29 samples out of 39 had an
undetectable level of CgA, irrespective of their origin.
When an intermediate mAb such as CGS04 was used, the
dispersion was improved although the concentrations of 8 samples
out of 39 were clearly diminished, including two samples with no
CgA. All samples from healthy individuals could be detected
(range 15–71 ng ml–1) and enabled us to fix the cut-off value at 67
ng ml–1. All these results clearly show that CGS06/CGS30* is the
closest combination to the reference RIA.
DISCUSSION
In the present study, 24 monoclonal antibodies were generated
against native and recombinant human CgA, and we report here
their characterization and the development of a sandwich IRMA
for hCgA.
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Figure 3 Comparison of three different immunoradiometric assays vs the
reference RIA. Data are expressed as the concentration ratio of pathological
plasma/95th percentile value of normal population (n = 20). Line segments
indicate the median value for each groupThe epitope analysis carried out raises several questions. The
experiment for the selection of a mAb pair showed that CGS04
perfectly detected rhCgA contained in calibrators, but failed to
recognize hCgA in PP when associated to any other mAb and irre-
spective of its position in the system. Similarly to CGS10, which
shows the same behaviour, it appears, therefore, that the proteo-
lysis recurrently affecting both ends of the protein (Gill et al, 1992;
Metz-Boutigue et al, 1993) is particularly active against the last
three, perhaps four, cleavage sites (373, 400, 409 and 437). It is
important to stress that the processing is complex and governed by
many different aspects. Among those, Strub et al (1997) showed
that proteolysis of bovine CgA could depend on post-translational
modifications. For instance, the putative cleavage site 373–374
may or may not constitute a proteolytic target, depending on the
phosphorylation of serine-380. In contrast, CGS21, whose epitope
considerably overlaps that of CGS04, behaves quite differently,
and its association with antibodies against the median part of
hCgA enables the detection of PP. Given the length of the
sequences deduced, it is most likely that the actual CGS04 epitope
is located in the C-terminal end of the 340–394 region; while
CGS21 recognizes the N-terminal part of the 356–400 sequence,
the cleavage site 373–374 is lying in between. The nature of the
CGS17 epitope remains unclear. Mapping with rhCgA peptides
indicates a very restricted sequence (339–355), upstream of the
CGS21 epitope. Surprisingly, CGS17 barely detects PP when
associated with median-type antibodies. Cleavage sites located
upstream do not seem to be involved either, as shown by a positive
association of CGS21 with the same antibodies. Strub et al (1997)
have described a phosphorylation site on serine-307 of bovine
CgA that is conserved in hCgA (ser-315) and, thus, close to the
CGS17 epitope. Differential phosphorylation of CgA in normal or
pathological tissues – through the activation of this mechanism in
tumours – may explain such a difference in terms of immunoreac-
tivity because the rhCgA against which CGS17 was raised is not
post-translationally modified.
Median-type mAb epitopes (CGS20, CGS06, CGS30) are likely
to recognize the CgA core as well. The three mAbs detect native
and recombinant hCgA equally well, although CGS20 and, above
all, CGS06 are close to two putative O-glycosylation targets (Strub
et al, 1997). Finally, CGS32 could not be addressed accurately.
Given its pattern (i.e. discrimination of the different pools), it is
probably directed against the median part of CgA. All these results
contradict to a certain extent the antigenic profiles already
described by Gill et al (1992) and Corti et al (1996b). It first
appears that most of the mAbs we obtained are directed against
regions of hCgA which were shown to be poorly antigenic by
these authors, apart from the CGS04 and CGS06 epitope groups
that match respectively the highly antigenic domains 375–394 and
222–230. Unexpectedly, none of the mAbs detected the N-
terminal third of the protein. This result remains unexplained
because both immunogens used contained hardly any truncated
hCgA. However, this part of the protein is well preserved among
different species and it may be less immunogenic.
As first published by O’Connor and Bernstein (1984), many
CgA immunoassays involved radiolabelled CgA and polyclonal
antibodies. In these configurations, CgA measurements reflect
levels of intact as well as truncated CgA. To detect most of these
entities, CGS06, against the 198–245 sequence of hCgA, was
chosen to develop a reference RIA. Results obtained with this
assay on a population of various neuroendocrine neoplasia were
consistent with previously described competition assays (data not
shown). Following the same assumption, we wanted to check
whether the association of CGS06 with other mAbs against CgA
could allow the assessment of total hCgA in a comparable manner.
The evaluation of all possible mAb combinations with three
plasma pools showed that only those systems involving mAbs
against the median domain of hCgA effectively discriminate. We
excluded all the combinations that detected rhCgA weakly
because the concentrations calculated may be inaccurate. For
instance, all combinations with the tracer CGS21 were eliminated.
In these cases, minor contaminations of calibrators by smaller
rhCgA fragments could be suspected, although they cannot have
such an influence in the second step of the assay. Moreover,
combinations with CGS04 as tracer, whose epitope is immediately
downstream from that of CGS21, perfectly detect increasing
concentrations of rhCgA. It is therefore very likely that radioiodi-
nation by chloramine T simply alters CGS21 immunoreactivity.
CGS10 reactivity seems to be affected to a lesser extent (apart
from in the CGS04/CGS10* system) for the same reasons. It must
be stressed that this problem could be ruled out when CGS10 was
replaced by CGS29, a mAb from the same group, for the last
comparative test, which confirmed yet again the full integrity of
the rhCgA calibrator.
Concerning the results obtained from the pathological pools, it
is clear that a major degradation occurs at the C-terminal end of
hCgA. Only combinations involving median-type mAbs against
the large domain 145–303 allow a reliable discrimination espe-
cially when corresponding epitopes are contiguous, as for CGS06
and CGS30. Besides, these data confirm that the cleavage site 208
separating the two epitopes is relatively unaffected. The final test
with systems associating immobilized CGS06 with other mAbs
spanning the CgA C-terminal domain confirms yet again the
assumptions made about the proteolysis of this region. The
involvement of the last cleavage sites (400, 409 and 437) is
obvious, not only with regard to the concentration measured in
pathological plasmas but also in normals for which half the popu-
lation assessed did not contain any hCgA. Only two samples from
carcinoid tumours were highly positive and comparable to the
levels obtained with the three other assays. However, this compar-
ison could not allow us to conclude the exact extent to which the
proteolysis occurs on the C-terminal domain, nor to establish a
relationship with the type of pathology. The degradation is
substantially less active upstream in the sequence, as shown by the
widespread dispersion obtained with CGS06/CGS04*. There
were, nevertheless, a fair number of samples for which the
majority of circulating hCgA was apparently truncated from the
373–439 domain, and perhaps from a wider part. The extension of
this study to the CGS06/CGS21* or CGS20* systems would be
necessary to confirm which of the three cleavage sites (322, 338 or
373) are processed preferentially.
The clinical value of CgA measurement relies on the detection
of all its circulating forms. Although it could be speculated that the
detection of a more restricted fragment could correlate to total
CgA measurement, it has been shown that the assessment of
plasma pancreastatin, produced by cleavage at the 243 and 294
dibasic sites, was less discriminative and of less clinical interest
than that of total CgA (Stridsberg et al, 1995). Our results show
that the hCgA C-terminal end is particularly affected by degrada-
tion, but that proteolysis decreases when moving upstream in the
sequence. They confirm those of Metz-Boutigue et al (1993) who
also found that this region is predominantly processed. Under
these circumstances, a mAb against the less affected median part
70 F Degorce et al
British Journal of Cancer (1999) 79(1), 65–71 © Cancer Research Campaign 1999of hCgA (CGS06) behaves in a comparable manner to a polyclonal
antibody, and thus allows the capture of a large number of CgA
entities. The association of this mAb with another one having a
contiguous epitope (CGS30) also enables the measurement of
major fragments and intact hCgA. After these results, this
immunoassay is readily included in several experimental proto-
cols, in order to evaluate its clinical value on larger populations as
well as on other neuroendocrine pathologies or mixed neoplasia.
In a first comparative study, Baudin et al (1998) show that CgA
was more sensitive than NSE in a population of patients with
gastroenteropancreatic neuroendocrine tumours, MTC and
phaeochromocytoma. The results obtained with this immunoradio-
metric assay also suggest that CgA may be more satisfactory than
neuron-specific enolase for the follow-up of such patients.
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